Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Budget Enhances Safety Programs, But Relies On Theoretical User Fees

Executive Summary

FDA proposes to increase its medical product safety spending by $100.8 million in the fiscal 2011 budget submitted to Congress Feb. 1

You may also be interested in...



Pediatric Labeling Extrapolation From Adults To Be Addressed In FDA Manual

FDA's Office of Pediatric Therapeutics expects to develop by 2012 a manual to guide agency staff on the use of extrapolation when assessing pediatric products and their development programs

Pediatric Labeling Extrapolation From Adults To Be Addressed In FDA Manual

FDA's Office of Pediatric Therapeutics expects to develop by 2012 a manual to guide agency staff on the use of extrapolation when assessing pediatric products and their development programs

FDA Biosimilars Program Gets Seed Money In Administration's FY '11 Budget

FDA plans to spend $5.7 million in fiscal 2011 to develop drug review standards and make other preparations for an approval pathway for follow-on biologics

Related Content

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel